omniture
logo
Search
礼进生物/LYVGEN
Media Room

Latest News

rss

Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients

* LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor...

2022-11-28 07:00 1922